UGCG and ovarian cancer: Results showed that GCS protein levels were decreased to 40%, 45%, 56% and 20% of control, respectively in drug-resistant human A2780-AD ovary cancer, KB-A1 cervical cancer, SW620/AD colon cancer, and murine EMT6/AR1 breast cancer cells treated with MBO-asGCS (50 nM, 7 days) (Figure 2A).